

## Mahajan, Vinay

---

**From:** Riemenschneider, Marion on behalf of Narasimhan, Vas  
**Sent:** Thursday, January 11, 2018 12:30 PM  
**Subject:** Important Organizational Announcement



Dear colleagues,

As you all know, I will be transitioning into my new role as CEO of Novartis [from February 1](#). We have made strong progress in our search for the new Head of Global Drug Development and I am confident we will have a permanent successor in place shortly. In order to help me focus on the new job, I have asked Rob Kowalski to take on the role of Head of GDD from February 1 until the new permanent GDD Head is in place, and I am delighted to announce that he has agreed to do so.

Rob, currently our Global Head of Regulatory Affairs and US Head of Development, is an incredibly accomplished leader at Novartis and in our industry. He is passionate about our organization and our purpose to develop medicines that extend and improve people's lives. Given his role as Head of RA, Rob also has an excellent overview of our entire portfolio and organization. In his interim role, Rob will work very closely with the DCN to maintain our momentum in building an intelligent, agile development organization that brings truly transformative medicines to patients around the world. Rob will also continue in his current role with members of the RA leadership team stepping up to support him for the duration of his interim role.

2018 is shaping up to be another exciting year for Development at Novartis and with all of your unwavering commitment, I'm confident that we will continue to deliver breakthroughs that change the practice of medicine.

Please join me in thanking Rob for taking on this important responsibility and wishing him the very best.

Kind regards,  
Vas

